Statins in Breast Cancer Therapy: Mechanistic Insights and Emerging Evidence

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Breast cancer (BC) is a leading global malignancy with rising incidence and economic burden.
• There is a critical need for accessible and effective therapeutic strategies, especially for low- and middle-income countries.
• Statins, used for hypercholesterolemia, are being investigated for their potential anticancer properties.

Purpose of the Study:

• To review the mechanistic basis and therapeutic potential of statin use, specifically simvastatin, in breast cancer.
• To synthesize evidence on statins' effects on cancer cell proliferation, survival, and metastasis.
• To evaluate the role of statins as repurposed drugs in the adjuvant treatment of breast cancer.

Main Methods:

• Review of preclinical studies on simvastatin's effects on breast cancer cell lines.
• Analysis of epidemiological and observational studies examining statin use and breast cancer outcomes.
• Synthesis of evidence from the past two decades regarding statin mechanisms and clinical implications.

Main Results:

• Statins inhibit the mevalonate pathway, impairing prenylation of key signaling proteins (e.g., Ras, Rho GTPases).
• Simvastatin demonstrated preclinical efficacy in inducing apoptosis, cell-cycle arrest, and inhibiting oncogenic pathways, particularly in hormone receptor-negative and triple-negative breast cancer (TNBC).
• Observational studies suggest a potential link between statin use and reduced BC recurrence and mortality.

Conclusions:

• Statins, particularly simvastatin, show promise as repurposed drugs for adjuvant breast cancer therapy due to their safety profile and accessibility.
• Disruption of the mevalonate pathway by statins offers a novel therapeutic approach for breast cancer.
• Further randomized controlled trials are essential to establish causality, define optimal regimens, and validate statins as adjunctive breast cancer treatments.